Vitamin D has direct antibacterial and antiviral properties
A large-scale study from the University of Surrey has drawn a meaningful statistical line between severe vitamin D deficiency and the risk of being hospitalized for respiratory infections — a finding that arrives at a moment when aging populations and strained health systems make such connections impossible to ignore. Examining the health records of more than 36,000 UK participants, researchers found that those with the lowest vitamin D levels faced a 33 percent higher hospitalization risk for conditions like pneumonia and bronchitis, while each incremental rise in vitamin D corresponded to a modest but consistent reduction in that risk. The study does not establish causation, but it adds weight to a growing body of evidence suggesting that something as accessible as a vitamin supplement may carry consequences for public health far beyond bone density. In a world where respiratory infections rank among the leading causes of death for older adults, the question of whether deficiency is quietly compounding that toll deserves serious attention.
- Severe vitamin D deficiency — levels below 15 nmol/L — is associated with a 33% higher chance of ending up hospitalized with a respiratory infection like pneumonia or bronchitis.
- The risk is not a simple on-off switch: every 10 nmol/L gain in vitamin D levels corresponds to a 4% drop in hospitalization risk, suggesting a continuous, dose-related relationship.
- Older adults and ethnic minority communities in the UK carry a disproportionate burden of both vitamin D deficiency and severe respiratory illness, making the findings especially urgent for these groups.
- Researchers from Surrey, Reading, and Oxford are calling for further investigation into whether winter supplementation programs and vitamin D-fortified foods could meaningfully reduce pressure on the NHS.
- The study, published in The American Journal of Clinical Nutrition, is described as the largest of its kind to examine this specific link, lending institutional weight to its implications for public health policy.
Researchers at the University of Surrey, working alongside colleagues from the Universities of Reading and Oxford, have identified a significant statistical association between severe vitamin D deficiency and hospitalization for respiratory infections. Drawing on health records from over 36,000 participants in the UK Biobank, the study found that people with vitamin D levels below 15 nanomoles per liter faced a 33 percent higher risk of being hospitalized for conditions such as pneumonia and bronchitis, compared to those with adequate levels of at least 75 nmol/L.
What makes the findings particularly notable is the dose-response pattern the team uncovered: for every 10 nmol/L increase in vitamin D, hospitalization risk fell by 4 percent. This suggests the relationship is gradual rather than a simple threshold effect — more vitamin D, across the range, correlates with better outcomes. Lead researcher Abi Bournot noted that vitamin D's role extends well beyond bone health, with antibacterial and antiviral properties that appear to help the body resist the pathogens behind respiratory illness. Yet many people, particularly during winter months when sunlight is scarce, fall short of the government's recommended daily intake of 10 micrograms.
The stakes are not abstract. For adults aged 50 to 74, lower respiratory tract infections already rank among the top 20 causes of death globally; for those 75 and older, they enter the top 10. Older adults and ethnic minority communities in the UK face disproportionately high rates of deficiency, compounding their vulnerability. Senior author Dr. Andrea Darling framed the results as a potential lever for reducing NHS hospitalizations — through targeted supplementation, fortified foods, or broader policy interventions — and called for further research to test that possibility. The study stops short of proving causation, but its scale and consistency make it difficult to set aside.
A team of researchers at the University of Surrey has found a measurable link between severe vitamin D deficiency and the likelihood of ending up in hospital with a respiratory infection. The study, which examined health records from over 36,000 people in the UK Biobank, discovered that those with dangerously low vitamin D levels—below 15 nanomoles per liter—faced a 33 percent higher risk of hospitalization for conditions like pneumonia and bronchitis compared to people with adequate vitamin D stores of at least 75 nanomoles per liter.
The research matters because respiratory infections are a significant public health burden, particularly as people age. For adults between 50 and 74, lower respiratory tract infections rank among the top 20 causes of death globally. For those 75 and older, they crack the top 10. Middle-aged and older adults are especially vulnerable to these infections, which can turn from uncomfortable to life-threatening quickly. When hospitalization becomes necessary, it strains already-stretched health systems and leaves individuals seriously ill.
The Surrey team, working with collaborators from the University of Reading and University of Oxford, analyzed the relationship between vitamin D status and respiratory infection hospitalizations in what they describe as the largest study of its kind to examine this connection. Beyond the headline finding about severe deficiency, the researchers uncovered a dose-response pattern: for every 10-unit increase in vitamin D levels, the hospitalization rate for respiratory infections dropped by 4 percent. This suggests the relationship is not simply a threshold effect but a gradual one, with more vitamin D correlating to lower risk across the range.
Abi Bournot, the lead researcher on the project, emphasized that vitamin D does more than support bone and muscle health. The vitamin possesses antibacterial and antiviral properties that appear to help the body fight off the pathogens that cause respiratory infections. Yet despite its importance, many people fall short of the government's recommended daily intake of 10 micrograms. The problem worsens during winter months when sunlight exposure—the body's primary source of vitamin D—becomes limited.
Bournot pointed out that certain populations face particular risk. Older people, who are already at higher risk of dying from respiratory infections, often have lower vitamin D levels. Ethnic minority communities in the UK also experience disproportionately high rates of vitamin D deficiency, a disparity that compounds their vulnerability to serious respiratory illness. For these groups, the findings carry urgent implications.
Dr. Andrea Darling, a senior author on the study, framed the results as a potential tool for reducing pressure on the National Health Service. If vitamin D supplementation—especially during winter—or increased consumption of vitamin D-fortified foods could meaningfully reduce hospitalizations for respiratory infections, the public health payoff would be substantial. The findings suggest this is worth investigating further through additional research and potentially through policy interventions.
The study was published in The American Journal of Clinical Nutrition, lending it credibility within the scientific community. The work does not prove that vitamin D deficiency causes respiratory infections or hospitalizations, but it does establish a strong statistical association that warrants attention. For individuals and for health systems already stretched thin, the message is straightforward: vitamin D status appears to matter for respiratory health, and ensuring adequate levels may be one lever for reducing serious illness.
Notable Quotes
Vitamin D is vital to our physical wellbeing. Not only does it keep our bones and muscles healthy, its antibacterial and antiviral properties are also thought to help reduce the risk of respiratory tract infections.— Abi Bournot, Lead Author, University of Surrey
Our findings point to the potential for vitamin D supplementation and consumption of vitamin D fortified foods to reduce the risk of hospitalization with respiratory infections in the future, and therefore mitigate pressures on the NHS.— Dr. Andrea Darling, Senior Author, University of Surrey
The Hearth Conversation Another angle on the story
Why does vitamin D specifically seem to protect against respiratory infections? Is it just about immunity in general?
It's more targeted than that. Vitamin D has direct antibacterial and antiviral properties—it's not just boosting your immune system broadly. It actually helps your body fight the specific pathogens that cause pneumonia and bronchitis. That's why the effect shows up so clearly in the data.
The study found a 33 percent increase in hospitalization risk. That's a big number. Does that mean one in three people with severe deficiency will end up in the hospital?
No, it's important to be precise about that. It means the rate is 33 percent higher than it is for people with adequate vitamin D. The absolute risk depends on many other factors—age, overall health, exposure to infection. But the relative increase is substantial enough that it matters at a population level.
Why does this matter for the NHS specifically? Isn't this just a health issue for individuals?
It's both. When you have 36,000 people in a study showing this pattern, you're looking at thousands of preventable hospitalizations across the country. Hospital beds, staff time, treatment costs—those are all strained resources. If vitamin D supplementation could reduce even a fraction of respiratory infection hospitalizations, that's real capacity freed up for other patients.
The study mentions ethnic minorities are at higher risk of deficiency. Why is that?
It's partly about skin pigmentation and sunlight exposure. Darker skin requires more sun exposure to produce the same amount of vitamin D. In a country like the UK with limited winter sunlight, that compounds the problem. There's also variation in diet and access to fortified foods. It's a disparity worth naming because it means the benefit of supplementation isn't evenly distributed.
So what happens next? Does this become a public health recommendation?
That's the open question. The researchers are calling for further study and suggesting this warrants policy consideration. But moving from "we found an association" to "everyone should supplement" requires more evidence and careful thinking about who benefits most and how to reach them effectively.